The news of BTIG analyst Julian Harrison maintaining a Buy rating on CymaBay Therapeutics and raising the price target from $18 to $22 is likely to have a positive impact on the company's stock in the short term. This is because such an upgrade usually signals the analyst's increased confidence in the company's future performance, which can encourage investors to buy the stock, potentially driving up its price.